Bystander effect from cytosine deaminase and uracil phosphoribosyl transferase genes in vitro: A partial contribution of gap junctions

Cancer Letters

Volumn 282, Issue 1, 2009, Pages 43-47

  Tanaka, Toshiaki ^a   Duflot Dancer, Agnès ^a   Tiraby, Michèle ^b   Piccoli, Colette ^a   Tiraby, Gérard ^b,c   Yamasaki, Hiroshi ^a   Mesnil, Marc ^a,d  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b Zone industrielle de Montaudran   (United States)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d UNIVERSITÉ DE POITIERS   (France)

Author keywords

Bystander effect; Cytosine deaminase; Gap junction; Gene therapy; Uracil phosphoribosyl transferase

Indexed keywords

COMPLEMENTARY DNA; CONNEXIN 43; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; URACIL PHOSPHORIBOSYLTRANSFERASE;

ARTICLE; BYSTANDER EFFECT; CANCER GENE THERAPY; CELL COMMUNICATION; CELL KILLING; CELL POPULATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVITY; GAP JUNCTION; GENE EXPRESSION; GENE VECTOR; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; METABOLIC ACTIVATION; PRIORITY JOURNAL; SUICIDE GENE THERAPY;

BYSTANDER EFFECT; CELL COMMUNICATION; CLONING, MOLECULAR; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GAP JUNCTIONS; GENE THERAPY; HELA CELLS; HUMANS; PENTOSYLTRANSFERASES;

EID: 67649390836     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.02.050     Document Type: Article

References (19)

1. Mullen C.A., Kilstrup M., and Blaese M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA 89 (1992) 33-37
2. Huber B.E., Austin E.A., Good S.S., Knick V.C., Tibbels S., and Richards C.A. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 53 (1993) 4619-4626
3. Huber B.E., Austin E.A., Richards C.A., Davis S.T., and Good S.S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA 91 (1994) 8302-8306
4. Rogers R.T., Ge J.Q., Holley-Guthrie E., Hoganson D.K., Comstock K.E., Olsen J.C., and Kenney S. Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and Herpes simplex virus thymidine kinase. Human Gene Ther. 7 (1996) 2235-2245
5. Rowley S., Lindauer M., Gebert J., Haberkorn U., Oberdorfer F., Moebius U., Herfarth C., and Schackert H.K. Cytosine deaminase gene as a potential tool for the genetic therapy of colorectal cancer. J. Surg. Oncol. 61 (1996) 42-48
6. Hirschowitz E.A., Ohwada A., Pascal W.R., Russi T.J., and Crystal R.G. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Human Gene Ther. 6 (1995) 1055-1063
7. Tiraby M., Cazaux C., Baron M., Drocourt D., Reynes J.P., and Tiraby G. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett. 167 (1998) 41-49
8. Elfgang C., Eckert R., Lichtenberg-Frate H., Butterweck A., Traub O., Klein R.A., Hulser D.F., and Willecke K. Specific permeability and selective formation of gap junction channels in connexin-transfected HeLa cells. J. Cell Biol. 129 (1995) 805-817
9. Mesnil M., Krutovskikh V., Piccoli C., Elfgang C., Traub O., Willecke K., and Yamasaki H. Negative growth control of HeLa cells by connexin genes: connexin species specificity. Cancer Res. 55 (1995) 629-639
10. Mesnil M., Piccoli C., Tiraby G., Willecke K., and Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA 93 (1996) 1831-1835
11. Haberkorn U., Oberdorfer F., Gebert J., Morr I., Haack K., Weber K., Lindauer M., Van Kaick G., and Schackert H.K. Monitoring gene therapy with cytosine deaminase: in vitro studies using tritiated-5-fluorocytosine. J. Nucl. Med. 37 (1996) 87-94
12. Bentires-Alj M., Hellin A.C., Lechanteur C., Princen F., Lopez M., Fillet G., Gielen J., Merville M.P., and Bours V. Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther. 7 (2000) 20-26
13. Adachi Y., Tamiya T., Ichikawa T., Terada K., Ono Y., Matsumoto K., Furuta T., Hamada H., and Ohmoto T. Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Human Gene Ther. 11 (2000) 77-89
14. Ichikawa T., Tamiya T., Adachi Y., Ono Y., Matsumoto K., Furuta T., Yoshida Y., Hamada H., and Ohmoto T. In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther. 7 (2000) 74-82
15. Wang Z., Cai L., and Wang H. Gene therapy of adenovirus mediated CD::upp/5-FC directed by GSTP1 promoter in cisplatin-resistant ovarian cancer. Gynecol. Oncol. 96 (2005) 643-650
16. Lu S., Wang X., Xiao L., Cai L., Zhang Y., Wang H., and Wang Z. Gene therapy for ovarian cancer using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene directed by MDR1 promoter. Cancer Biol. Ther. 6 (2007) 397-404
17. Bourbeau D., Lavoie G., Nalbantoglu J., and Massie B. Suicide gene therapy with an adenovirus expressing the fusion gene CD::UPRT in human glioblastomas: different sensitivities correlate with p53 status. J. Gene Med. 6 (2004) 1320-1332
18. Khatri A., Zhang B., Doherty E., Chapman J., Ow K., Pwint H., Martiniello-Wilks R., and Russell P.J. Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice. J. Gene Med. 8 (2006) 1086-1096
19. Mesnil M., and Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 60 (2000) 3989-3999